Genzyme

GenzymeGenzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

www.genzyme.com

Genzyme RSS Channel

Display # 
Title Published Date
Sanofi Genzyme announces recipients of Patient Advocacy Leadership (PAL) awards 06 January 2016
Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care 05 October 2015
Genzyme recognizes World MS Day 30 May 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients 22 January 2012
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration 16 November 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis 12 July 2011
Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform 17 June 2011
Genzyme Revenues Grow in First-Quarter 2011 29 April 2011
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease 15 April 2011
Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares 07 March 2011
Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program 28 February 2011
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year 16 February 2011
Genzyme Will Allow sanofi-aventis to Conduct Due Diligence 31 January 2011
Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme® 20 January 2011
Genzyme Financial Recovery Continues in Fourth Quarter 11 January 2011
Genzyme Statement on Discussions With Sanofi-Aventis 10 January 2011
Genzyme Details Market Potential of Alemtuzumab for MS 20 December 2010
Genzyme Reiterates Board's Position on sanofi-aventis Tender Offer 13 December 2010
Genzyme Completes Sale of Genetic Testing Business to LabCorp 01 December 2010
Genzyme Announces Agreement to Sell Diagnostics Business 18 November 2010

Most Popular Now

Boehringer Ingelheim increases acce…

Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an eas...

Read more

FDA approves first buprenorphine im…

The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designe...

Read more

Fasting-like diet reduces multiple …

Evidence is mounting that a diet mimicking the effects of fasting has health benefits beyond weight loss, with a new USC-led study indicating that it may reduce symptoms ...

Read more

AstraZeneca licenses Zurampic to Gr…

AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin Ameri...

Read more

Exercise, future anticancer therapy…

Several studies have demonstrated the benefits of exercise to improve the quality of life of people with cancer. But Dr. Fred Saad, urologist-oncologist and researcher at...

Read more

Merck announces survey results expl…

Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks as...

Read more

Promising treatment prospects for i…

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms...

Read more

Pfizer presents promising data from…

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, nex...

Read more

Merck Accelerator expands its reach…

Merck, a leading science and technology company, has started this week the application period for the next round of its Accelerator programs in Darmstadt, Germany, and Na...

Read more

Bayer Science & Education Found…

Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambit...

Read more

New class of protein could treat ca…

A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therap...

Read more

Boehringer Ingelheim and Harvard sc…

Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]